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It is well established that materials employed for med-
ical diagnostic and therapeutic purposes require bio-
compatibility testing before human use, as evidenced
by the comprehensive and general guide to biocompat-
ibility testing published in the International Standard
ISO-10993 [1]. Similarly, in hemodialysis, biocompati-
bility profiling has become a prerequisite for any new
membrane that is developed [2–5]. This requirement has
been in response to the recognition that biocompatibility
may play an important role both in acute intradialytic
symptoms and chronic morbidities associated with
hemodialysis therapy, such as susceptibility to infection,
osteodystrophy, and amyloidosis. Today, biocompatibil-
ity profiling of peritoneal dialysis (PD) solutions has be-
come an important feature of both conventional and new
dialysis solution performance [6–11].
It is now over 20 years since the in vitro detrimen-
tal effects of commercial dialysis solution on phagocyte
function were first described [12]. Since this time, there
has been a plethora of reports describing a wide variety
of approaches, techniques, and results of biocompatibil-
ity PD solution testing. The impetus for this proliferation
of research is the growing belief that the first genera-
tion of commercially available PD solutions that have low
pH, high lactate and glucose concentrations, are hyper-
osmolar, and contain glucose degradation products that
may be causally associated with some of the complica-
tions of PD therapy [7, 8, 13–19]. Examples of the latter
are pain upon infusion in the acute setting and loss of
ultrafiltration in the long-term patient. The aim of this
review is to discuss definitions of biocompatibility, the
hierarchical testing schemes that are often selected for
biocompatibility testing, how these schemes relate to
contemporary models of structural and functional alter-
ations of the peritoneal membrane, and the associated
clinical consequences. Finally, an example of how the re-
sults of such a biocompatibility testing scheme helped to
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optimize the development of a new, physiologic pH and
bicarbonate-lactate based solution, Physioneal.
DEFINITIONS OF BIOCOMPATIBILITY
In 1994, the Consensus Conference on Biocompatibil-
ity defined biocompatibility as “the ability of a material,
device or system to perform without a clinically signifi-
cant host response in a specific application.” [20] This is an
uncontroversial definition, but it is suggested that an en-
hancement may include the term a “clinically significant
undesirable host response” assuming all host responses
are not undesirable. This definition mandates human clin-
ical evaluation and thus, for practical purposes during the
research and development phases of new PD solutions
or when more immediate insights into biocompatibility
characteristics are required, alternative definitions have
been proposed. In 1993, Holmes [9] defined PD solution
biocompatibility as the biological effect that the solution
exerts on the normal functioning of the tissues and cells
of the peritoneum during both uninfected and infected
states. This definition best lends itself to acute in vitro
testing methods. Subsequently, Di Paolo [21] proposed
that biocompatibility of PD solutions should include
“the capacity to leave the anatomical and physiological
characteristics of the peritoneum unchanged in time.”
Obviously, this definition is tailored to the use of ani-
mal models and clinical trials for biocompatibility evalu-
ations, and does bring the important concept of the effect
over time of any given formulation. Recent observations
on structural changes in the peritoneal membrane over
time on PD by the International Peritoneal Biopsy Reg-
istry, as described by Williams [22] in this supplement,
clearly show that progressive alterations take years to
manifest, emphasizing the challenge that lies in the in-
terpretation of biocompatibility testing systems in which
exposure times and conditions are often significantly dif-
ferent from those of the clinical situation. The latter limi-
tation is particularly evident with in vitro systems, and to
some extent even with animal models, although the de-
velopment of long-term chronic dialysis models in recent
years provides more relevant data [23–25].
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Fig. 1. A hierarchical representation of biocompatibility testing. The
progression from in vitro to clinical studies usually results in a level
of increasing clinical relevance, with a corresponding increase in the
demand of expertise and resources.
THE HIERARCHY OF BIOCOMPATIBILITY
TESTING
Biocompatibility evaluations described in the scien-
tific literature usually can be categorized into the fol-
lowing approaches: in vitro cell culture systems; in vivo
animal models; clinical studies of in vivo response; or clin-
ical outcome studies. Figure 1 describes a typical hier-
archical representation of these approaches in terms of
clinical relevance and degree of difficulty. In vitro assay
systems often provide early indications of the biocom-
patibility performance of a dialysis solution, potentially
providing input into the design of a new formulation, and
importantly minimizing the need for future animal stud-
ies. As in vitro assay systems are almost uniformly much
less technically and resource demanding than animal
models, data from such studies constitute the prepon-
derance of biocompatibility reports in the scientific lit-
erature. In this supplement, Hoff reviews extensively the
wealth of in vitro assay systems that have been selected to
date to assess PD solution biocompatibility. In vitro data
can form the initial basis for concern over a seemingly
bioincompatible performance of a dialysis solution. How-
ever, it should be always kept in mind that the frequent
use of single cell types combined with culture condi-
tions and solutions’ exposure methods that do not closely
mimic the in vivo experience limits the interpretation of
such data. Similarly, the seemingly biocompatible perfor-
mance of a new solution in vitro during its development
cannot assure that in vivo or clinical indices will follow
suit. The progression to animal models in order to pro-
vide in vivo biocompatibility performance usually consti-
tutes the next phase of evaluation before human exposure
(Fig. 1). Obviously, the benefit of in vivo exposure in
which all peritoneal cell and tissue types and exposed si-
multaneously is evident. Nevertheless, the usefulness of
animal data clearly depends upon how well the model re-
capitulates the human disease [21]. In the field of PD
models, recent advances in the development of long-
term models with minimal infection have permitted more
meaningful solution biocompatibility testing [23, 25–27].
The advantages and disadvantages of various PD animal
models are discussed by ter Wee in this supplement. How-
ever, certain circumstances exist, even with long-term ani-
mal models, which limit their interpretation. For example,
the use of nonuremic animals is typical in this field.
The transition from in vitro and animal model preclin-
ical testing to clinical evaluation now poses the oppor-
tunity to obtain early biocompatibility performance data
using surrogate markers of peritoneal structure and func-
tion prior to the challenging task of performing human
clinical outcome studies (Fig. 1). Topley et al describe typ-
ical clinical study designs in this supplement using in vivo
markers of peritoneal membrane status, intraperitoneal
inflammation, and peritoneal cell function. Fundamen-
tally, clinical studies of in vivo response to a PD solution
involve the assessment of changes in either effluent mark-
ers of inflammation, angiogenesis, and fibrosis present in
patient dialysis effluent after timed in vivo dwell of the
solution. Additionally, assessment of cell viability and
function, usually macrophages isolated from effluent, can
be included. The interpretation of the clinical relevance
of such data depends upon the strength of the evidence
supporting a pathogenic role for the mediator, cell, or cell
function selected for study.
Despite the caveats associated with each stage of bio-
compatibility testing, it is proposed that information from
studies higher in the hierarchy should supersede that
obtained from other studies lower in the hierarchy if
inconsistencies occur. Ultimately, the relevance of all bio-
compatibility testing will need to be established through a
combination of registry data, both outcome and biopsy in
content and, whenever feasible, using the gold standard
of randomized controlled clinical outcome trials.
Structural and functional correlates
of biocompatibility testing
During the last five years, an increased understanding
into the temporal structural changes of the peritoneal
membrane, as described by Williams in this supplement,
has also been accompanied by significant insights into the
molecular and cellular pathobiology of peritoneal mem-
brane dysfunction [28–37]. Combined, these observations
have led several lead investigators in the field to construct
hypothetical models that attempt to unify this informa-
tion [38–40]. For the generalist, interpretation of bio-
compatibility studies in relation to these contemporary
models can be challenging. For instance, in this supple-
ment, there are reviews covering a variety of biocompati-
bility testing approaches of Physioneal, a new pH neutral
bicarbonate-lactate based PD solution. The combination
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Fig. 2. A contemporary model of peritoneal membrane dysfunction that provides detail of potential effectors and mediators of structural and
function membrane alteration in the long-term patient. The corresponding contribution of in vitro and animal model biocompatibility methods to
each aspect of the model is provided. Modified from Miyata et al: Kidney Int 61:375–386, 2002.
of in vitro, animal, clinical studies of in vivo response, and
clinical outcome studies, were employed to optimize the
solution formulation during development and demon-
strate benefit of the final formulation. How do such bio-
compatibility studies provide insight into contemporary
models of membrane dysfunction? To illustrate, a re-
cent and sophisticated hypothetical model proposed by
Miyata et al [39] describing alterations of the peritoneal
membrane in long-term patients who experience ultra-
filtration failure has been selected and then modified to
include biocompatibility studies and their corresponding
utility (Figs. 2 and 3). Figure 2 illustrates where in vitro
biocompatibility assays systems and animal model evalu-
ations can provide insight into each of aspect of the hypo-
thetical model. The roll and utility of clinical studies of in
vivo response and clinical outcome studies to provide fur-
ther insight into the effects of PD solutions on membrane
dysfunction, as described by this model, are shown in
Figure 3. It can be seen that each of the test methods
chosen within a biocompatibility evaluation program will
augment and compliment each other, ultimately provid-
ing a comprehensive understanding of the biocompatibil-
ity performance of any given solution formulation.
Biocompatibility and new PD solution development:
A case study
Having described an overview of biocompatibility eval-
uation strategies and hierarchical testing schemes, the
following section provides a case study describing how
a biocompatibility evaluation plan optimized the formu-
lation development of a bicarbonate-based physiologic
pH solution, Physioneal. Prior to the development of
Physioneal, it had already been established that several
factors were important in the biocompatibility perfor-
mance of conventional PD solutions. These consisted of
the low pH of the formulations, their lactate content, and
the presence of glucose as the osmotic agent. Glucose
contributes to bioincompatibility by virtue of its intrinsic
metabolic, gene activating properties, its hyperosmolal-
ity at the concentrations employed, and because it is the
source of glucose degradation products, some of which
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Fig. 3. A contemporary model of peritoneal membrane dysfunction that provides detail of potential effectors and mediators of structural and
function membrane alteration in the long-term patient. The corresponding contribution of clinical studies of in vivo response and membrane
function to each aspect of the contemporary model membrane dysfunction is provided. Modified from Miyata et al: Kidney Int 61:375–386, 2002.
may be cytotoxic and/or contribute to carbonyl stress.
Hoff more extensively reviews these factors in this sup-
plement. Reduction in total glucose exposure, glucose
degradation products, hyperosmolality, and low pH can
be partly addressed by the use of nonglucose-based solu-
tions containing icodextrin or amino acids [41]. However,
as these formulations cannot be used for all dialysis ex-
changes, until a safe and affordable alternative to glucose
is identified, there remains the need for glucose-based
solutions that have been optimized in their biocompati-
bility performance. Possible improvements in biocompat-
ibility of glucose-based PD solutions therefore required
the development of a PD solution that could be infused
at a physiologic pH, contain an alternative buffer sys-
tem, and provide a reduced glucose degradation product
content.
In order to avoid caramelization of dextrose, glucose-
based solutions have to be formulated at a pH of maxi-
mum 5.5. At pH values above this value excessive glucose
degradation occurs, rendering the formulation unaccept-
able for human use. Container designs that permit sepa-
ration of dextrose from lactate in a two-chambered bag
allowed the adjustment of the pH of the lactate compart-
ment to a higher level, and the glucose at a more acidic
pH value. This design permits a pH level of 6.0 to 6.5 after
mixing of the two chambers and a significant reduction in
most glucose degradation products [42]. However, a pH
of 7.4 still cannot be achieved with this improvement as
lactate has most of its buffering capacity in a pH range
of 3 to 5, with very minor buffering capacity at a pH of
6.0 to 6.5, resulting in unstable solutions in the upper pH
range at a pH of 4 to 6.
From the discussion above, it is clear that the pH of the
PD solution can be increased further by adding a solution
buffer with a good buffering action in a pH range around
7.4. Bicarbonate is an ideal candidate for PD solutions
as it provides the physiologic buffer of the extracellu-
lar space, while providing a solution buffering action in
the correct pH range (5.5 to 7.5). Due to advancements
in container and packaging technologies in recent years,
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the ability to manufacture a stable bicarbonate-based PD
solution became feasible. Early clinical development
work resulted in the conclusion that bicarbonate-based
PD solution would need concentrations of bicarbonate
ion in the range of 35 to 40 mmol/L for adequate acid-
base control. Although bicarbonate is regarded as the
primary physiologic buffer, it was unclear if supraphysio-
logic concentrations of bicarbonate would be biocompat-
ible [43–45]. Likewise, although it had been reported that
exposure to high levels of carbon dioxide, as experienced
during laparoscopic surgery, can decrease macrophage
cytokine release, the effect of chronic exposure to lower,
yet still supraphysiologic levels of CO2 remained unclear
[46]. The clinical impact of higher than physiologic bi-
carbonate and pCO2 is unknown, but at least one study
indicated that high pCO2 levels might have undesired
side effects [47]. In addition, Schambye et al reported
that a clear difference existed between buffer systems
containing bicarbonate alone and mixtures of bicarbon-
ate and other buffers using an in vitro assay of neutrophil
migration [48–54]. Henderson and Martis therefore pro-
posed a combination of 25 mmol/L bicarbonate plus 10 to
15 mmol/L lactate as an alternative formulation to pure
bicarbonate for optimal biocompatibility [55]. This for-
mulation was proposed to provide improved biocompati-
bility by proving a physiologic level of bicarbonate, pCO2,
and pH, while at the same time ensuring the highest level
of safety. Because it was unknown whether the presence
of supraphysiologic bicarbonate and pCO2 present in a
pure bicarbonate formulation would be disadvantageous
relative to lower levels of lactate, but now at neutral pH,
with the mixed-buffer formulation, a series of biocom-
patibility studies comparing the two formulations were
conducted using in vitro, ex vivo, and clinical designs.
In vitro studies using a variety of cell types and as-
say conditions to compare pure bicarbonate and bicar-
bonate/lactate mixtures consistently revealed that both
of these formulations were significantly more biocom-
patible than the conventional acidic lactate-based solu-
tions with higher glucose degradation product content
[56]. However, no differences between bicarbonate alone
and bicarbonate-lactate formulations could be detected,
suggesting equivalent biocompatibility. Due to the limita-
tions of in vitro studies as described above, it was consid-
ered prudent to seek additional information using clinical
indices of biocompatibility.
Associated with a Phase II clinical trial, biocompat-
ibility studies were conducted to compare the in vivo
response to bicarbonate alone and the mixed-buffer
solution [57]. The design and results of these stud-
ies are extensively reviewed by Topley in this supple-
ment. Briefly described, patients were exposed in a
randomized crossover manner to either bicarbonate or
bicarbonate/lactate solution after initial exposure to the
control lactate solution, all within three consecutive days.
After short intraperitoneal dwell periods permitting in
vivo exposure, peritoneal macrophages were isolated
from effluent and assessed for function using the re-
lease of both unstimulated and stimulated tumor necro-
sis factor a (TNFa). When solutions containing the
lower glucose concentration of 1.36% were employed,
macrophage function was significantly improved with
both bicarbonate-based solutions versus the control so-
lutions, interpreted by a higher release of stimulated
TNFa, with no change in cytokine secretion when un-
stimulated. The response of macrophages exposed to
the bicarbonate/lactate solution was significantly better
than that seen with the bicarbonate alone formulation.
Furthermore, a significant improvement in cell function
was only seen with the bicarbonate/lactate mixture when
3.86% glucose-based solutions were employed. Invoking
the hierarchy of biocompatibility relevance, the results of
these Phase II clinical studies suggested that the bicarbon-
ate/lactate formulation was to be superior to bicarbonate
alone in biocompatibility performance, despite equiva-
lence seen in earlier in vitro reports.
In an ideal world, this line of investigative research
should have been pursued to its logical end—a multicen-
ter, randomized, controlled study comparing each formu-
lation with hard end points, such as ultrafiltration failure
rates. However, the conduct of such a study is viewed as
impractical due to logistical considerations, as insightfully
described by Coles [58]. Nevertheless, pain upon infu-
sion, although uncommon, was selected as a clinical end
point for study in a randomized, double-blind, crossover
study and proposed as index of biocompatibility [59].
The results of this study are reviewed by Lindholm et al
in this supplement. Briefly, the effects of a 38 mmol/L
bicarbonate solution, a bicarbonate/lactate solution
(Physioneal), and standard solution on infusion pain were
assessed using a verbal rating scale and the validated
McGill Pain Questionnaire. Both of the test solutions
resulted in a highly statistically significant reduction in
inflow pain compared to the control lactate solution. Al-
though differences were not large, for all pain variables
assessed, the bicarbonate/lactate solution was reported
to be more effective than the bicarbonate alone solu-
tion in alleviating pain. The combination of these clinical
outcome observations with the in vivo clinical response
studies led to the logical choice of the bicarbonate/lactate
formulation as the final choice for further clinical devel-
opment. The latter case study reveals the utility of a struc-
tured and comprehensive biocompatibility testing plan
during new PD solution formulation development. In this
particular case study, by following a biocompatibility test
plan that transitioned from in vitro to clinical studies of
in vivo response and clinical outcome studies, it was pos-
sible to identify an optimal formulation that could not
have been achieved using theoretical considerations or
in vitro studies alone.
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CONCLUSION
In recent years we have witnessed the development of a
wide variety of approaches to the assessment of PD solu-
tion biocompatibility. These methodologies have grown
to include an expanding array of in vitro, animal, and
ex vivo techniques. Concurrently, the result of basic and
clinical research into the molecular and cellular path-
ways involved in the structural and functional changes
seen in some long-term patients has provided insight into
the pathobiology of peritoneal membrane failure. These
observations have permitted the development of several
contemporary models of membrane dysfunction in the
long-term patient. This review attempts to illustrate how
biocompatibility testing schemes can provide valuable
information on each component of these contemporary
models. Furthermore, the use of a hierarchical and struc-
tured biocompatibility testing scheme to help direct and
optimize the development of a novel bicarbonate/lactate
based PD solution is provided.
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